TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
// Yinan Yao 1, * , Hequan Li 1, * , Junjun Chen 1 , Weiyi Xu 2 , Guangdie Yang 1 , Zhang Bao 1 , Dajing Xia 3, 4 , Guohua Lu 1 , Shuwen Hu 1 , Jianying Zhou 1 1 Department of Respiratory Diseases, First Affiliated Hospital of Zhejiang University, Hangzhou, China 2 Department of Clinical Laboratory, First Affiliated Hospital of Zhejiang University, Hangzhou, China 3 School of Public Health, Zhejiang University, Institute of Immunology, Zhejiang University, Hangzhou, China 4 Institute of Immunology, Zhejiang University, Hangzhou, China * These authors have contributed equally to this work Correspondence to: Jianying Zhou, email: zjyhz@zju.edu.cn Hequan Li, email: lihequan@zju.edu.cn Keywords: TREM-2, lung cancer, IL-10, Syk, immunoregulation Received: October 20, 2015 Accepted: March 28, 2016 Published: April 18, 2016 ABSTRACT During infection, triggering receptor expressed on myeloid cells-2 (TREM-2) restrains dendritic cells (DCs) and macrophages (MΦs) phagocytosis, as well as reduces pro-inflammatory cytokines release through DNAX-activation protein 12 (DAP12) signaling. However, the role of TREM-2 signaling in cancer has never been elucidated. In the current study, we found that TREM-2 was up-regulated on peripheral blood monocytes in tumor-bearing host. More TREM-2 + DCs were detected in the lung of 3LL tumor-bearing mice. On the other hand, the level of TREM-2 on pulmonary MΦs positively correlated with the pathological staging of lung cancer. However, surgical or chemotherapeutic reduction of tumor burden led to the obvious decline of TREM-2. In vitro, TREM-2 expression of bone marrow (BM)-derived DCs and MΦs was induced by conditional medium (CM) containing the supernatant of 3LL cells. TREM-2 + DCs from CM and/or tumor-bearing mice held altered phenotypes (CD80 Low CD86 Low MHCII Low ) and impaired functions, such as, reduced interleukin (IL)-12 secretion, increased IL-10 production, and weakened ovalbumin (OVA)-endocytic capacity; also developed potent inhibitory effect on T cell proliferation that could be partially reversed by TREM-2 blockage. Moreover, spleen tyrosine kinase (Syk) inhibitor restrained IL-10 production of TREM-2 + DC. Remarkably, IL-10 neutralizing antibody and Syk inhibitor both lowered the suppressive potential of TREM-2 + DCs in T cell proliferation. Also, adoptive transfer of this TREM-2 + DCs accelerated the tumor growth rather than jeopardized survival in lung cancer-bearing mice. In conclusion, these results indicate that TREM-2 might act as a negative immuno-regulatory molecule through Syk pathway in an IL-10 dependent manner and partially predicts prognosis in lung cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655 · cited 1×
“TNM staging was determined according to the 7th TNM classification [33].”
Tumor-derived lactic acid modulates dendritic cell activation and antigen expression
Gottfried, E., Kunz-Schughart, L. A., Ebner, S., Mueller-Klieser, W., Hoves, S., Andreesen, R., Mackensen, A., & Kreutz, M. (2006) · Blood · doi:10.1182/blood-2005-05-1795 · Cited by 729
TREMs in the immune system and beyond
Colonna, M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1106 · Cited by 701
Cutting Edge: TREM-2 Attenuates Macrophage Activation
Turnbull, I. R., Gilfillan, S., Cella, M., Aoshi, T., Miller, M., Piccio, L., Hernandez, M., & Colonna, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3520 · Cited by 688
Bouchon, A., Hernández-Munain, C., Cella, M., & Colonna, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1111 · Cited by 460 · cited 2×
“Hitherto, TREM-2 was considered to be expressed on immature monocyte derived DC, newly recruited peritoneal and alveolar MΦs, and BM-derived MΦs [10, 12, 14], but not on circulating monocytes or tissue-resident MΦs [10].”
Hamerman, J. A., Jarjoura, J. R., Humphrey, M. B., Nakamura, M. C., Seaman, W. E., & Lanier, L. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2051 · Cited by 440 · cited 3×
“Hitherto, TREM-2 was considered to be expressed on immature monocyte derived DC, newly recruited peritoneal and alveolar MΦs, and BM-derived MΦs [10, 12, 14], but not on circulating monocytes or tissue-resident MΦs [10].”
TREM and TREM-like receptors in inflammation and disease
Ford, J. W., & McVicar, D. W. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.009 · Cited by 434
Takahashi, K., Prinz, M., Stagi, M., Chechneva, O., & Neumann, H. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040124 · Cited by 414 · cited 1×
“TREM-2 functioned to inhibit TNF-α and IL-6 production by MΦs in response to TLR ligands [10], whereas overexpression in myeloid cells led to less TNF and inducible nitric oxide [19], but more IL-10 [19, 20].”
TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1
Peng, Q., Malhotra, S., Torchia, J. A., Kerr, W. G., Coggeshall, K. M., & Humphrey, M. B. (2010) · Science Signaling · doi:10.1126/scisignal.2000500 · Cited by 413
Ito, H., & Hamerman, J. A. (2012) · European Journal of Immunology · doi:10.1002/eji.201141679 · Cited by 173 · cited 3×
“Recent studies found that TREM-2 paired with DAP12 had a critical role in the negative regulation of DC and MΦ activation upon TLR ligation [9, 10, 13, 14].”
Cited by
The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway
Deczkowska, A., Weiner, A., & Amit, I. (2020) · Cell · doi:10.1016/j.cell.2020.05.003 · Cited by 648
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Zhang, H., Liu, L., Liu, J., Dang, P., Hu, S., Yuan, W., Sun, Z., Liu, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01725-x · Cited by 389
Self-citationSingle-cell protein activity analysis identifies recurrence-associated renal tumor macrophages
Obradovic, A., Chowdhury, N., Haake, S. M., Ager, C., Wang, V., Vlahos, L., Guo, X. V., Aggen, D. H., Rathmell, W. K., Jonasch, E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.038 · Cited by 349
TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
Qiu, H., Shao, Z., Wen, X., Jiang, J., Ma, Q., Wang, Y., Huang, L., Ding, X., & Zhang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716710 · Cited by 32
“elucidated that, compared with normal control, TREM2 was dramatically overexpressed on peripheral blood monocytes and TAMs of patients with lung cancer and tumor-bearing mice, and there was a positive correlation between the level of TREM2 on pulmonary macrophages and the pathological staging or lymph nodes metastasis…”
Li, Z., Ma, L., Chen, M., Chen, X., Sha, M., & Hang, H. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2024.101275 · Cited by 11
“22,23 The transforming growth factor-b (TGF b ) communication network is multifunctional in tumors and promotes metastasis, attenuates CD8+ T cell activation, enhances myo fi broblast differentiation, and enhances extracellular matrix deposition.”
Metadata
- Authors
- Yao, Y., Li, H., Chen, J., Xu, W., Yang, G., Bao, Z., Xia, D., Lu, G., Hu, S., & Zhou, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-04-18
- Volume
- 7
- Issue
- 20
- Pages
- 29620-29634
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2338711703
- Cited by
- 49
- References
- 12
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer. https://app.cochat.ai/papers/10.18632/oncotarget.8813
- The paper
- Yao, Y., Li, H., Chen, J., Xu, W., Yang, G., Bao, Z., Xia, D., Lu, G., Hu, S., & Zhou, J. (2016). TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer. Oncotarget. https://doi.org/10.18632/oncotarget.8813
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.